Literature DB >> 21793988

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

A-P Magiorakos1, A Srinivasan, R B Carey, Y Carmeli, M E Falagas, C G Giske, S Harbarth, J F Hindler, G Kahlmeter, B Olsson-Liljequist, D L Paterson, L B Rice, J Stelling, M J Struelens, A Vatopoulos, J T Weber, D L Monnet.   

Abstract

Many different definitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria are being used in the medical literature to characterize the different patterns of resistance found in healthcare-associated, antimicrobial-resistant bacteria. A group of international experts came together through a joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC), to create a standardized international terminology with which to describe acquired resistance profiles in Staphylococcus aureus, Enterococcus spp., Enterobacteriaceae (other than Salmonella and Shigella), Pseudomonas aeruginosa and Acinetobacter spp., all bacteria often responsible for healthcare-associated infections and prone to multidrug resistance. Epidemiologically significant antimicrobial categories were constructed for each bacterium. Lists of antimicrobial categories proposed for antimicrobial susceptibility testing were created using documents and breakpoints from the Clinical Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the United States Food and Drug Administration (FDA). MDR was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, XDR was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) and PDR was defined as non-susceptibility to all agents in all antimicrobial categories. To ensure correct application of these definitions, bacterial isolates should be tested against all or nearly all of the antimicrobial agents within the antimicrobial categories and selective reporting and suppression of results should be avoided.
© 2011 European Society of Clinical Microbiology and Infectious Diseases. No claim to original US government works.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793988     DOI: 10.1111/j.1469-0691.2011.03570.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  2000 in total

1.  Antimicrobial resistance in mastitis, respiratory and enteric bacteria isolated from ruminant animals from the Atlantic Provinces of Canada from 1994-2013.

Authors:  Babafela B Awosile; Luke C Heider; Matthew E Saab; J T McClure
Journal:  Can Vet J       Date:  2018-10       Impact factor: 1.008

2.  Antimicrobial action of 1,10-phenanthroline-based compounds on carbapenemase-producing Acinetobacter baumannii clinical strains: efficacy against planktonic- and biofilm-growing cells.

Authors:  Roberta F Ventura; Anna Clara M Galdino; Livia Viganor; Ricardo P Schuenck; Michael Devereux; Malachy McCann; André L S Santos; Ana Paula F Nunes
Journal:  Braz J Microbiol       Date:  2020-07-31       Impact factor: 2.476

3.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

4.  Clinical epigenetics and multidrug-resistant bacterial infections: host remodelling in critical illness.

Authors:  Ettore Crimi; Giuditta Benincasa; Silvia Cirri; Rebecca Mutesi; Mario Faenza; Claudio Napoli
Journal:  Epigenetics       Date:  2020-04-14       Impact factor: 4.528

5.  Increased multi-drug resistant Escherichia coli from hospitals in Khartoum state, Sudan.

Authors:  M E Ibrahim; N E Bilal; M E Hamid
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

6.  Induction of human plasmablasts during infection with antibiotic-resistant nosocomial bacteria.

Authors:  Victor I Band; Chris Ibegbu; Surinder Pal Kaur; Stephanie M Cagle; Ronald Trible; Crystal L Jones; Yun F Wang; Colleen S Kraft; Susan M Ray; Jens Wrammert; David S Weiss
Journal:  J Antimicrob Chemother       Date:  2014-02-28       Impact factor: 5.790

7.  Time series analysis as a tool to predict the impact of antimicrobial restriction in antibiotic stewardship programs using the example of multidrug-resistant Pseudomonas aeruginosa.

Authors:  Matthias Willmann; Matthias Marschal; Florian Hölzl; Klaus Schröppel; Ingo B Autenrieth; Silke Peter
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

8.  IS5 element integration, a novel mechanism for rapid in vivo emergence of tigecycline nonsusceptibility in Klebsiella pneumoniae.

Authors:  Lindsey E Nielsen; Erik C Snesrud; Fatma Onmus-Leone; Yoon I Kwak; Ricardo Avilés; Eric D Steele; Deena E Sutter; Paige E Waterman; Emil P Lesho
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 9.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

10.  High incidence and endemic spread of NDM-1-positive Enterobacteriaceae in Henan Province, China.

Authors:  Shangshang Qin; Ying Fu; Qijing Zhang; Hui Qi; Jian Guo Wen; Hui Xu; Lijuan Xu; Li Zeng; Hao Tian; Lijuan Rong; Yonghong Li; Lihong Shan; Hongde Xu; Yunsong Yu; Xianju Feng; Hong-Min Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.